Editorial: Cholecystectomy and nafld: Does gallbladder removal have metabolic consequences

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 959-961

  Nervi, Flavio ^a   Arrese, Marco ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; FARNESOID X RECEPTOR; FATTY ACID; FIBROBLAST GROWTH FACTOR 19; GLUCAGON LIKE PEPTIDE 1; MEMBRANE PROTEIN; PROTEIN TGR5; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; CAUSAL ATTRIBUTION; CHOLECYSTECTOMY; ECHOGRAPHY; ENERGY METABOLISM; FATTY ACID SYNTHESIS; GALLBLADDER DISEASE; GALLBLADDER FUNCTION; GALLSTONE; GLUCOSE METABOLISM; HEALTH SURVEY; HUMAN; HYPERTRANSAMINASEMIA; LIPID METABOLISM; LIVER CIRCULATION; LIVER CIRRHOSIS; METABOLIC REGULATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; FATTY LIVER; FEMALE; MALE; NOTE;

CHOLECYSTECTOMY; FATTY LIVER; FEMALE; GALLSTONES; HUMANS; MALE;

EID: 84878899072     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.84     Document Type: Review

References (37)

1. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013 (in press).
2. Stinton LM, Shaff er EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012 ; 6 : 172-87.
3. Riquelme A, Arrese M, Soza A et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009 ; 29 : 82-8.
4. Miquel JF, Covarrubias C, Villaroel L et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998 ; 115 : 937-46. (Pubitemid 28452942)
5. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Th er 2007 ; 25 : 883-9.
6. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006 ; 368 : 230-9. (Pubitemid 44037798)
7. Mendez-Sanchez N, Arrese M, Zamora-Valdes D et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007 ; 27 : 423-33. (Pubitemid 46534563)
8. Biddinger SB, Haas JT, Yu BB et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008 ; 14 : 778-82.
9. Adams LA, Lymp JF, St Sauver J et al. Th e natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 ; 129 : 113-21. (Pubitemid 41002048)
10. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 2011 ; 140 : 508-16.
11. Kullak-Ublick GA, Paumgartner G, Berr F. Long-term eff ects of cholecystectomy on bile acid metabolism. Hepatology 1995 ; 21 : 41-5.
12. Krondl A, Vavrinkova H, Michalec C. Eff ect of Cholecystectomy on the Role of the Gall Bladder in Fat Absorption. Gut 1964 ; 5 : 607-10.
13. Roda E, Aldini R, Mazzella G et al. Enterohepatic circulation of bile acids aft er cholecystectomy. Gut 1978 ; 19 : 640-9. (Pubitemid 8388157)
14. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the United States population. Am J Gastroenterol 2013 ; 108 : 952-8 (this issue).
15. NCHS. National Health and Nutrition Examination Survey (NHANES). Available at: http://www.cdc.gov/nchs/nhanes.htm (cited 02 February 2013).
16. Koller T, Kollerova J, Hlavaty T et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol 2012 ; 47 : 197-203.
17. Fracanzani AL, Valenti L, Russello M et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One 2012 ; 7 : e41183.
18. Ramos-De la Medina A, Remes-Troche JM, Roesch-Dietlen FB et al. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justifi ed? J Gastrointest Surg 2008 ; 12 : 2097-102.
19. Nervi F, Miquel JF, Alvarez M et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006 ; 45 : 299-305. (Pubitemid 44026566)
20. Ioannou GN. Cholelithiasis, cholecystectomy, and liver disease. Am J Gastroenterol 2010 ; 105 : 1364-73.
21. Lefebvre P, Cariou B, Lien F et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009 ; 89 : 147-91.
22. Matsubara T, Li F, G onzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2012.
23. Pols TW, Noriega LG, Nomura M et al. Th e bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011 ; 29 : 37-44.
24. Trauner M, Claudel T, Fickert P et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010 ; 28 : 220-4.
25. Jones SA. Physiology of FGF15/19. Adv Exp Med Biol 2012 ; 728 : 171-82.
26. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fi broblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012 ; 26 : 312-24.
27. Fu L, John LM, Adams SH et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-defi cient diabetes. Endocrinology 2004 ; 145 : 2594-603. (Pubitemid 38686202)
28. Tomlinson E, Fu L, John L et al. Transgenic mice expressing human fi broblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002 ; 143 : 1741-7. (Pubitemid 34415889)
29. Zweers SJ, Booij KA, Komuta M et al. Th e human gallbladder secretes fi broblast growth factor 19 into bile: towards defi ning the role of fi broblast growth factor 19 in the enterobiliary tract. Hepatology 2012 ; 55 : 575-83.
30. Keitel V, Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012 ; 36 : 412-9.
31. Li T, Holmstrom SR, Kir S et al. Th e G protein-coupled bile acid receptor, TGR5, stimulates gallbladder fi lling. Mol Endocrinol 2011 ; 25 : 1066-71.
32. Pols TW, Noriega LG, Nomura M et al. Th e bile acid membrane receptor TGR5 as an emerging target in metabolism and infl ammation. J Hepatol 2011 ; 54 : 1263-72.
33. Sonne DP, Hare KJ, Martens P et al. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastrointest Liver Physiol 2012.
34. Ali RB, Cahill RA, Watson RG. Weight gain aft er laparoscopic cholecystectomy. Ir J Med Sci 2004 ; 173 : 9-12. (Pubitemid 38811994)
35. Amigo L, Husche C, Zanlungo S et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int 2011 ; 31 : 52-64.
36. Barrera F, Molina HR, Azocar L et al. Cholecystectomy changes the diurnal rhythm and reduces serum levels of fgf19 coupled with a raise in bile acid synthesis. (Abstract). Hepatology 2011 ; 54 : 728A.
37. Eren F, Kurt R, Ermis F et al. Preliminary evidence of a reduced serum level of fi broblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 2012 ; 45 : 655-8.